Tendyne Announces First Patient Enrolled in US Trans-Catheter Mitral Valve Replacement Trial

Tendyne Holdings, Inc. ("Tendyne") a privately held clinical stage medical device company, announced today the Tendyne Bioprosthetic Mitral Valve was successfully implanted in the first patient in the United States as part of a multi-center global feasibility study that aims to provide early insights into the safety and performance of the Tendyne Bioprosthetic Mitral Valve System in patients with symptomatic mitral regurgitation of degenerative or functional etiology.


Tendyne Holdings, Inc. is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of thousands of individuals worldwide every year.

Formed in 2010, our first product concept is a transcatheter mitral valve replacement prosthesis for the treatment of mitral regurgitation. The intent is for the valve to be deployed and secured with no disruption
to the native mitral annulus while preserving the sub-valvular apparatus. Placement of the valve is intended
to be completed transapically in a simple procedure where the implanting physician is able to re-position, remove, and re-deploy our valve throughout the procedure.

Tendyne was acquired by Abbott in September 2015.


©2014 Tendyne Holdings, Inc.

Tendyne’s products are not approved for investigational use or sale in the United States.